A5086970175- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Cancer Immunotherapy and Biomarkers
- HER2/EGFR in Cancer Research
- Advanced Breast Cancer Therapies
- Global Cancer Incidence and Screening
- Gene expression and cancer classification
- Lung Cancer Research Studies
- COVID-19 and healthcare impacts
- Ferroptosis and cancer prognosis
- Cancer-related molecular mechanisms research
- Cancer Treatment and Pharmacology
- RNA modifications and cancer
- Estrogen and related hormone effects
- Breast Lesions and Carcinomas
- BRCA gene mutations in cancer
- Radiomics and Machine Learning in Medical Imaging
- Prostate Cancer Treatment and Research
- Cancer Diagnosis and Treatment
- Cervical Cancer and HPV Research
- COVID-19 Clinical Research Studies
- Medical Imaging Techniques and Applications
- Nutrition, Genetics, and Disease
- Genital Health and Disease
Universidad Privada San Juan Bautista
2019-2025
Group for the Analysis of Development
2021-2024
Henry Ford Health System
2024
EsSALUD
2014-2023
Thomas Jefferson University Hospital
2022
Charité - Universitätsmedizin Berlin
2022
Mount Sinai Health System
2022
Jefferson University Hospitals
2022
Prince Charles Hospital
2022
The University of Queensland
2022
Neoadjuvant chemotherapy (NAC) induces a pathologic complete response (pCR) in approximately 30% of patients with triple-negative breast cancers (TNBC). In lacking pCR, NAC selects subpopulation chemotherapy-resistant tumor cells. To understand the molecular underpinnings driving treatment-resistant TNBCs, we performed comprehensive analyses on residual disease 74 clinically defined TNBCs after NAC, including next-generation sequencing (NGS) 20 matched pretreatment biopsies. Combined NGS and...
BackgroundThere are well-known differences in gender outcome non-small cell lung cancer (NSCLC) and other cancers. In this work, we evaluated several randomised clinical trials to explore the influence of patients with NSCLC treated targeted therapy immunotherapy.MethodsWe performed a series meta-analysis compare routine setting for overall survival progression-free (PFS) phase III comparing EGFR inhibitors versus chemotherapy (OPTIMAL, LUX-lung 3, 6, EURTAC, ENSURE WTJOG); ALK (ASCEND 4,...
JAK2 amplification decreases survival in triple-negative breast cancer but can be targeted with JAK2-specific inhibitors.
Abstract Purpose: Although breast cancers are known to be molecularly heterogeneous, their metabolic phenotype is less well-understood and may predict response chemotherapy. This study aimed evaluate genes as individual predictive biomarkers in cancer. Experimental Design: mRNA microarray data from cancer cell lines were used identify bimodal genes—those with highest potential for robust high/low classification clinical assays. Metabolic function was evaluated vitro the scoring gene, lactate...
Triple negative breast cancer (TNBC) is the most aggressive form of with limited options targeted therapy. Recent findings suggest that clinical course TNBC may be modified by presence tumor-infiltrating lymphocytes (TILs) and chemokine's expression, such as CCL5. Diverse studies have shown CCL5 suppresses anti-tumor immunity it has been related to poor outcome in different types while other studies, this gene a better outcome. We sought determine association recruitment TILs immune cells....
Abstract DDIT4 gene encodes a protein whose main action is to inhibit mTOR under stress conditions whilst several in vitro studies indicate that its expression favors cancer progression. We have previously described an independent prognostic factor for tripe negative breast resistant neoadjuvant chemotherapy. herein report high related the outcome (recurrence-free survival, time progression and overall survival) types. performed silico analysis online platforms, pooled datasets from KM...
Breast parenchymal density is considered a strong indicator of breast cancer risk and therefore useful for preventive tasks. Measurement often qualitative requires the subjective judgment radiologists. Here we explore an automatic composition classification workflow based on convolutional neural networks feature extraction in combination with support vector machines classifier. This compared to assessments seven experienced The experiments yielded average kappa value 0.58 when using mode...
Radical new possibilities of improved treatment cancer are on offer from an advanced medical technology already demonstrating its significance: next-generation sequencing (NGS). This refined testing provides unprecedentedly precise diagnoses and permits the use focused highly personalized treatments. However, across regions globally, many patients will continue to be denied benefits NGS as long some yawning gaps in implementation remain unattended. The challenges at regional national levels...
Introduction Human papillomavirus (HPV) infection is a common sexually transmitted often associated with cancer development. This study aimed to estimate the prevalence of HPV in women receiving care at AUNA healthcare network Peru. Methods We conducted an observational, descriptive, cross-sectional, retrospective study. A de-identified database HPV-positive who underwent BD Onclarity™ Assay between December 2018 and 2021 Auna clinics was analyzed. The contained information regarding age,...
Residual disease after neoadjuvant chemotherapy (NAC) in triple-negative breast cancer (TNBC) is related with poor prognosis; however, the risk of recurrence 3 years from surgery, becomes similar to other subtypes indicating that TNBC composed tumours different prognosis. To evaluate genes aggressiveness outcome resistant NAC, we profiled 82 samples residual whose expression for 449 was quantified NanoString. The validation set (GSE25066) consisted 113 cases disease. stepwise multivariate...
Abstract The genomic characteristics of Peruvian patients with gastric adenocarcinoma from diverse socioeconomic backgrounds were examined in consideration the possibility that different may be exposed to risk factors. We conducted a prospective pilot study two cities (Lima and Ica). This enrolled 15 low status (LSES) medium/high (MHSES). profiling samples was done through FoundationOne CDx platform. compared need for targeted therapy immunotherapy between LSES MHSES. genes higher rates...
Cervical cancer is the leading malignant neoplasm in Peruvian women. This malignancy a public health problem and several efforts were previously performed to develop control plans. Geographical, cultural, structural, infrastructural procedural barriers can limit implementation of such strategies. Several previous studies have characterized human papilloma virus (HPV) epidemiology, where prevalence high-risk HPV adult females ~12% cervical 90-95%. The predominant for are lack specialists...
There are different biological and clinical patterns of lung cancer between genders indicating intrinsic differences leading to increased sensitivity cigarette smoke-induced DNA damage, mutational KRAS better outcomes in women while at gene-expression levels was not previously reported. Here we show an enrichment immune genes NSCLC compared men. We found a GSEA analysis (by processes annotated from Gene Ontology) six public datasets repeated observation gene sets women. "Immune system...
Immunotherapy has changed the landscape of cancer treatment and significantly improved outcome several types including breast, lung, colorectal prostate. Neoantigen recognition immune checkpoint inhibitors are nowadays milestones different immunotherapeutic regimes; however, high cost, primary acquired resistance variability responses make their extensive use difficult. The development better predictive biomarkers that represent tumour diversity shows promise because there is a significant...
To determine the frequency of PIK3CA mutations in a Peruvian cohort with HER2-amplified and triple negative breast cancers (TNBC).We analyzed two cohorts 134 primary non-metastatic cancer patients from Peru. Cohorts consisted 51 hormone receptors (+)/HER2-amplified tumor surgically resected as first treatment included ALTTO trial (ALTTO cohort) 81 TNBC residual disease after neoadjuvant (neoadjuvant cohort). Genomic DNA was extracted paraffin-embedded samples. Samples were taken at biopsies...